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Introduction
The activation of complement and its deleterious con-
sequences have been observed in many renal diseases.
Complement contributes to injury in several forms of
glomerulonephritis (GN), in acute and chronic humo-
ral rejection after renal transplantation, and at the time
of ischaemiaureperfusion injury. It is also thought to
accelerate the progression of chronic renal damage.
Most of the evidence for the role of complement in
enhancing injury comes from experimental data
obtained in murine models, in which the addition of
complement inhibitors blocks or reduces damage. The
first evidence that excessive complement activation
can be reversed in humans has been recently reported
by Remuzzi et al. [1]. These authors reported a com-
bined liver and kidney transplantation in a young child
with haemolytic uraemic syndrome (HUS) and a muta-
tion of factor H by which they were able to restore
the defective factor H activity with no recurrence of
the disease. The biological markers of complement
activation normalized after transplantation as well.
In contrast to inhibitors of the coagulation cascade,
the clinical application of complement inhibitors has
not yet started; this might explain why so little atten-
tion has been given by clinicians to this field. With
major progresses made in the last 10 years on the
engineering of molecules, it is likely that complement
inhibition will be introduced in clinical practice soon.
Here we would like to emphasize some of the aspects of
complement relevant to renal diseases, for which speci-
fic inhibitors of complement might produce beneficial
effects, but also the possible caveats related to the inhi-
bition of an enzymatic cascade central to the normal
function of the innate immune system.
Complement
The complement system consists of more than 20 pro-
teins, which interact in a cascade sequence (Figure 1).
The biological effects of this system include: (i) opsoni-
zation and phagocytosis mainly due to the covalent
binding of C3b to the targets; (ii) inflammation
through the production of anaphylaxis (C3a, C5a)
and chemotaxis (C5a), with C5a playing the major
role; (iii) insertion of the membrane attack complex
(MACsC5b–9 complex) on pathogens, but also on
bystander cells, which are activated; (iv) enhancement
of the immune response by the covalent binding of C3
fragments [2]; (v) removal of immune complexes (ICs)
by blocking their formation and dissolving large
immune aggregates, or by delivering ICs to the fixed
macrophages [3]; and (vi) silent removal of apoptotic
bodies by C1q and classical pathway activation [4,5].
The system may be activated via the classical, alter-
native or lectin pathways. The classical pathway is
activated by the binding of complement component C1
to the Fc portions of antibody molecules complexed
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with antigen. The lectin pathway is activated by the
binding of mannan-binding lectin (which is struc-
turally related to C1q) to bacterial carbohydrates.
The resulting activation of C3 can be amplified by
a positive feedback loop, which is also called the
alternative pathway since its continuous low-grade
physiological activation can be amplified directly on a
pathogen or a foreign surface where no complement
regulatory proteins are present.
Complement regulators
Complement activation is tightly regulated by a number
of circulating and cell-bound proteins. This regulation
is delicately balanced between the need to effectively
destroy invading microorganisms and to prevent exces-
sive activation of autologous cells and tissues. Three
of these regulators inhibit complement at its most
crucial step, i.e. the formation of the C3uC5 con-
vertases; thus, they have the potential to abrogate
most biological functions of complement including
the release of C5a and formation of MAC. Whereas
decay accelerating factor (DAF, CD55) is expressed
only at low levels in glomeruli and tubules, membrane-
cofactor protein (MCP, CD46), is present on almost
all cells in the kidney. Interestingly, complement recep-
tor 1 (CR1, CD35), which is on a molar basis the
most powerful inhibitor of the C3 convertases, is
expressed only on podocytes. The fourth regulator,
CD59, interferes with the insertion of the C5b–9 com-
plex in the cell membrane and is present on glomerular
and distal tubular cells, but less so on proximal tubules.
In addition to these membrane-bound inhibitors, many
other soluble proteins in plasma and extravascular
fluids may down-regulate complement, e.g. factor H,
which blocks activation at the C3 convertase step, and
clusterin which interferes with the normal assembly
of MAC.
Complement in glomerulonephritis
Although it has been known since the advent of
immunofluorescence techniques that many types of
GN are characterized by deposition of complement
proteins such as C1q, C4 and C3 fragments and
MAC, their role in initiating or mediating local
damage has remained controversial in human dis-
eases. Of interest for the present discussion are
reports analyzing some rare conditions of continuous
activation of the alternative pathway that result in
glomerular damage. The deficiency of factor H is
responsible for a loss of control of the alternative
pathway with continuous activation of C3. In pigs,
factor H deficiency leads to the development of
membranoproliferative GN (MPGN) with dense de-
posits, i.e. a syndrome very similar to the human
MPGN type II observed in patients with nephritic
factor (NeF) and in some very rare patients with
factor H deficiency as well [6]. The administration to
the pigs of purified factor H, so as to keep the
alternative pathway under control, prevents the forma-
tion of the immune deposits and subsequent glom-
erular damage, and even when administered later,
allows a regression of the nephritis [7]. Patients with
NeF, an IgG autoantibody that prolongs the enzy-
matic half-life of the C3 convertase (C3bBb) thus
producing continuous C3 activation in plasma,
develop MPGN in ;50% of cases. In this condition,
the main glomerular deposits consist of C3 fragments
as well, and the clinical syndrome is one of heavy
proteinuria and progressive loss of renal function
resulting in end-stage renal disease. Thus, comple-
ment blockade is a real target for therapy in these
exceptional diseases, in which little immunoglobulin
(Ig) deposits are found. In contrast, most human GN
are characterized by Ig deposits (IgA, membranous,
membranoproliferative and lupus GN), so that com-
plement activation is very probably secondary to the
local deposition or formation of immune aggregates.
Although various models in rabbits and mice indicate
that under many circumstances complement is
directly involved in local injury, it may be that in
some cases local complement activation may not be
deleterious. Recent data obtained in C3 knockout
mice suggest that complement may have protective
functions by preventing local accumulation of immune
complexes [8], particularly in the autologous phase
of nephrotoxic nephritis induced by heterologous
anti-GBM antibodies. Robson et al. [9], using C1q
knockout mice, provided evidence that C1q plays a
direct role in preventing inflammation and damage
in a similar model. Such a protective role for com-
plement activation, i.e. dissolution of immune aggre-
gates, was suggested many years ago by Bartolotti
et al. [10] and later by Furness and Turner [11]. In
conclusion, although complement-blocking agents
might be beneficial in various forms of GN, inhibition
of complement should be performed only under strict
clinical investigation protocols.
Ischaemiaureperfusion injury
In most organs, including the heart and the intestine,
the ischaemiaureperfusion injury is best explained by
the presence of natural Ab, which recognize novel
epitopes expressed by endothelial cells and activate
complement by the classical pathway [12]. The situa-
tion might be different in the kidney, where neither
natural Ab [13] nor the classical pathway of com-
plement [14] appears to be involved. Tubular cells
are more sensitive to hypoxia than endothelial cells so
that the damage is mainly localized to tubules rather
than vessels [14]. Tubular cells when hypoxicunecrotic
were shown to activate complement by the alternative
pathway, and most of the local injury was due to the
assembly of the membrane attack complex. It is
important to realize that tubular cells produce all
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necessary proteins for alternative pathway function,
which may explain why ischaemiaureperfusion injury in
the kidney is very resistant to complement inhibitors
[15]. Furthermore, many other mediators may partici-
pate in tubular necrosis in ischaemiaureperfusion
injury. The data do not exclude a role for complement
in ischaemiaureperfusion injury in humans, which
might be different from the animal models studied,
but the evidence to date does not favour such a hypo-
thesis. Even in the immediate post-transplantation
period, the occurrence of acute tubular necrosis,
which is most frequently due to ischaemic injury, is
not accompanied by evidence of complement activa-
tion on endothelial cells in the kidney; in particular,
there is no C4d deposition in peritubular capillaries
[16].
Antibody- and complement-mediated rejection
after renal transplantation (humoral rejection)
In recent years, the role of alloAb-mediated acute and
chronic rejection has been emphasized with evidence
for complement activation by the classical pathway
being provided mainly by the peritubular capillary
deposition of C4d, the fragment of C4 that binds
covalently to nearby structures [17]. However, one very
rarely finds other complement fragments at the same
localization, which is somewhat surprising, since C3
has the same capacity as C4 to bind covalently to local
structures. The experimental models used to date have
shown clearly that Ab-mediated rejection is comple-
ment dependent, although in these models it is not
difficult to demonstrate C3 deposition in the kidney.
Thus, while there is no doubt that C4d is a good
marker for Ab-mediated humoral rejection, what
remains undetermined is whether the activation and
deposition of C4 is followed by damaging complement
activation or not. Only further clinico-pathological
investigations will provide us with an answer. In
clinical renal transplantation, ;5–10% of recipients
suffer from acute humoral rejection, and the rejection
episode is often resistant to steroid and antilympho-
cyte therapy [18]. New therapeutic approaches using
plasmapheresis, tacrolimus, mycophenolate mofetil
and intravenous immunoglobulin (IVIg) have been
shown to be useful in treating acute humoral rejection,
but complement inhibitors have not been used in this
setting in humans [19]. Another interesting aspect will
be that complement inhibitors may block hyperacute
rejection due to natural Ab, such as blood group Ab.
This situation is identical to the hyperacute rejection
seen during the first minutes of xenotransplantation,
where the immediate deposition of natural Ab (mainly
IgM in humans) brings about an explosive and
devastating activation of complement with ensuing
endothelial damage, followed by bleeding and throm-
bosis. In contrast to ischaemiaureperfusion injury in
the kidney, where the alternative pathway is mainly
damaging, it is evident that to treat or prevent
antibodyucomplement-mediated damage after renal
transplantation the classical pathway has to be inhi-
bited, and this at a very early phase of the enzymatic
cascade [20,21].
Progression of renal damage
Complement may contribute to the progression of
tubulointerstitial injury in renal diseases with pro-
teinuria, since the filtered complement proteins are
activated at the surface of proximal tubular cells by
the alternative pathway [22]. Complement partici-
pates in the renal damage in various models of chro-
nic diseases such as hypertensive nephropathy [23].
Clusterin knockout mice develop a chronic progressive
glomerulopathy characterized by mesangial immune
deposits, suggesting that under physiological con-
ditions, clusterin protects against glomerular damage
[24]. Increasing the local expression of clusterin has
shown beneficial effects in ischaemic brain damage
[25,26], and interestingly the expression of clusterin is
up-regulated in nephritis [27]. Taken together, the data
are suggestive that complement blockade might be
useful in the prevention of chronic damage. Because
this is an important clinical problem, even small
improvements in the general strategies to fight chronic
progression of renal damage might be important for
patients.
Complement inhibition
A complete and long-term inhibition of complement
may have some detrimental side effects, as suggested
by observations made in patients with various com-
plement deficiencies. Such patients have an increased
susceptibility to infection (mainly encapsulated bac-
teria including meningococci) and immune-complex
diseases. However, in many human diseases only short-
term inhibition would be needed, e.g. in ischaemiau
reperfusion injury or in acute humoral rejection in
transplantation. In addition, it is quite possible that
down-regulation rather than blockade of complement
may be sufficient on many occasions. Thus, although
we should be cautious with inhibiting complement, it
would be unwise not to start clinical investigations
because of potential side effects which may be
prevented (e.g. immunization against meningococci)
or for which a close surveillance can be proposed. For
the time being some complement inhibitors have
already reached clinical phase I and II studies. Two of
them are soluble recombinant CR1 and single-chain
Fv antibody against C5 [28].
It has not been the purpose here to discuss further
complement inhibitors [29], but rather to emphasize the
clinical conditions in which complement is directly res-
ponsible for renal damage. Clinical studies require large
financial investments nowadays, and few pharmaceu-
tical companies are ready to engage on large studies
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without any initial evidence for a possible beneficial
effect. It is unlikely that nephrologists will be the
first to handle complement inhibitors even in clinical
research areas, since the possible positive effects of
complement blockade in the many diseases described
here may not be readily apparent, either because
it would require the inclusion of many patients
(blockade of C5b–9 in ischaemiaureperfusion, humoral
rejection) or because long-term studies would be
required (GN or progression of renal disease). There is,
however, some hope that once more rare diseases
might bring the proof of principle required. In patients
with factor H deficiency, soluble recombinant CR1 may
block immediately the excessive activation of comple-
ment and restore C3 levels. In patients with GN, long-
term inhibition of complement could prevent further
deterioration of renal function, and in some patients
with HUS, might block the clinical syndrome.
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